Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 16, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 14, 2025.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$82.68 Published $91.73 Target $92.13 Window close $94.27 Peak
$80.01 – $81.94Entry zone — fair-value band
$82.68Published — price the day we called it
$91.73Target — the price the thesis aimed for
$94.27Peak — highest point inside the window, not a realized return
$92.13Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 89 days.

Peak price
$94.27
peak on November 14, 2025 — not a realized return
Peak gain
+14%
peak, from the publication price
Window close
$92.13
end-of-window price, context only
Days to target
89
Window
August 16, 2025 – November 14, 2025

The thesis — published August 16, 2025

Predicted growth
+13%
over the measurement window
Target price
$91.73
the price the thesis aimed for
Entry zone
$80.01 – $81.94
the fair-value band we waited for
Price at publication
$82.68
published August 16, 2025
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck mixes steady, dependable cash coming in with a strong, upward price trend and upbeat investor mood. The stock looks inexpensive versus its industry and the S&P 500, which can help support the price. Buying interest has been heavier than usual, but the price feels a bit hot, so buying small dips makes sense. Over the next 3 months, cancer drugs, vaccines, and the dividend may extend gains unless trial results or policy shocks hit.

Primary drivers

  • Shares look cheap versus profits, so value-focused buyers may step in.
  • The price trend is up, and the recent average price keeps rising steadily.
  • Investor mood is upbeat, with more buying than usual in recent sessions.
  • Reliable cash generation and a steady dividend can cushion downturns.

How it played out

MRK: target reached in 89 days

Lyra published MRK at $82.68 on 2025-08-16 with a short-term view for 13% growth toward $91.73. The thesis pointed to cheap shares versus profits, an upward price trend, upbeat investor mood, heavier buying, reliable cash generation, and a steady dividend. It also named cancer drugs, vaccines, and the dividend as possible support over the next 3 months.

Inside the window, MRK reached the target. The stock peaked at $94.27 on 2025-11-14, with a 14% gain, and the target was reached in 89 days. It ended at $92.13. The published thesis played out.

What happened during the window

On 2025-10-30, Merck reported third-quarter 2025 results, with sales of $17.28 billion and adjusted earnings per share of $2.58. On 2025-11-14, Merck agreed to buy Cidara Therapeutics in an all-cash deal worth $9.2 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals